AI Terminal
SYNAIRGEN PLC
Remuneration Information • Oct 21, 2021
7941_dirs_2021-10-21_493e058a-6253-42ef-92e2-02a77a82c383.html
Remuneration Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 7334P
Synairgen plc
21 October 2021
Press Release
Synairgen plc
('Synairgen' or the 'Company')
Grant of options
Southampton, UK - 21 October 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta (IFN-beta) for the treatment of severe viral lung infections, announces that on 20 October 2021 the Board of Synairgen granted options ('Options') over 428,502 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share to employees of Synairgen Research Limited, a wholly-owned subsidiary of the Company. The Options represent in aggregate 0.21 per cent. of the Company's issued share capital.
Following this grant, Synairgen has 8,463,223 options in issue, representing 4.20 per cent. of the Company's issued share capital.
Included in the number of Options granted as above, the following Options were issued to Persons Discharging Managerial Responsibilities ('PDMR'), who have no other holdings of ordinary shares or options in the Company:
| PDMR | Options Issued |
| Brooke Clarke | 113,636 |
| Richard Francis | 113,636 |
| Gareth Walters | 120,779 |
The Options are issued under the Company's Long Term Incentive Plans and are exercisable up to 19 October 2031, subject to the achievement of appropriate performance criteria.
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Brooke Clarke, Head of Communications
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone
Tel: +44 (0) 20 3709 5700
MK Strategies, LLC (US Media Relations)
Mary Conway
Tel: +1 516 606 6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. Granted Fast Track status from the US Food and Drug Administration (FDA) and deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR), Synairgen's Phase III clinical programme is currently evaluating nebulised SNG001 in patients across 17 countries. In a Phase II trial in hospitalised COVID-19 patients, SNG001 demonstrated a greater than two-fold chance of recovery to 'no limitation of activities' versus placebo.1
Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.
References
1 - https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
| a) | Name | Brooke Clarke |
| 2. | Reason for notification | |
| a) | Position / status | Head of Communications |
| b) | Initial notification / amendment | Initial Notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Synairgen plc |
| b) | LEI | 213800IMMTOPPDF8HD24 |
| 4. | Details of the transaction(s): | |
| a) | Description of the financial instrument Identification code |
Options over ordinary shares of 1p each GB00B0381Z20 |
| b) | Nature of the transaction | Award of Options under the Company's share plans |
| c) | Price(s) and volume(s) | 113,636 Options awarded |
| d) | Aggregated information Aggregated volume Price |
n/a |
| e) | Date of the transaction | 20 October 2021 |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
| a) | Name | Richard Francis |
| 2. | Reason for notification | |
| a) | Position / status | Head of CMC |
| b) | Initial notification / amendment | Initial Notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Synairgen plc |
| b) | LEI | 213800IMMTOPPDF8HD24 |
| 4. | Details of the transaction(s): | |
| a) | Description of the financial instrument Identification code |
Options over ordinary shares of 1p each GB00B0381Z20 |
| b) | Nature of the transaction | Award of Options under the Company's share plans |
| c) | Price(s) and volume(s) | 113,636 Options awarded |
| d) | Aggregated information Aggregated volume Price |
n/a |
| e) | Date of the transaction | 20 October 2021 |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
| a) | Name | Gareth Walters |
| 2. | Reason for notification | |
| a) | Position / status | Chief Regulatory Officer |
| b) | Initial notification / amendment | Initial Notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Synairgen plc |
| b) | LEI | 213800IMMTOPPDF8HD24 |
| 4. | Details of the transaction(s): | |
| a) | Description of the financial instrument Identification code |
Options over ordinary shares of 1p each GB00B0381Z20 |
| b) | Nature of the transaction | Award of Options under the Company's share plans |
| c) | Price(s) and volume(s) | 120,779 Options awarded |
| d) | Aggregated information Aggregated volume Price |
n/a |
| e) | Date of the transaction | 20 October 2021 |
| f) | Place of the transaction | Outside a trading venue |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHMMBRTMTTTBFB